주요 특징
-
Contains all-new chapters on COVID-19, vaccine hesitancy, and non-specific effects of vaccines, as well as significantly revised content on new vaccine technologies such as mRNA vaccines, emerging vaccines, and technologies to improve immunization.
-
Presents exciting new data on evolution of adjuvants across the centuries, dengue vaccines, human papillomavirus vaccines, respiratory syncytial virus vaccines, tuberculosis vaccines, and zoster vaccines.
-
Provides up-to-date, authoritative information on vaccine production, available preparations, efficacy and safety, and recommendations for vaccine use, with rationales and data on the impact of vaccination programs on morbidity and mortality.
-
Provides complete coverage of each disease, including clinical characteristics, microbiology, pathogenesis, diagnosis, and treatment, as well as epidemiology and public health and regulatory issues.
-
Keeps you up to date with information on each vaccine, including its stability, immunogenicity, efficacy, duration of immunity, adverse events, indications, contraindications, precautions, administration with other vaccines, and disease-control strategies.
-
Covers vaccine-preventable diseases, vaccine science, and licensed vaccine products, as well as product technologies and global regulatory and public health issues.
-
Analyzes the cost-benefit and cost-effectiveness of different vaccine options.
-
Helps you clearly visualize concepts and objective data through an abundance of tables and figures.
-
Enhanced eBook version included with purchase. Your enhanced eBook allows you to access all of the text, figures, and references from the book on a variety of devices.
| ISBN | 9780323790581 |
|---|---|
| 도서 구분 | 일반도서 |
| Publication Date | 2023 |
| Author Information | By Walter A. Orenstein, MD, DSc (HON), Professor of Medicine and Pediatrics, and Global Health, Emory University; Associate Director, Emory Vaccine Center, Atlanta GA; Bill & Melinda Gates Foundation, Seattle, WA; Former Director, National Immunization Program, Centers for Disease Control and Prevention, Atlanta GA ; Paul A. Offit, MD, Chief, Division of Infectious Diseases, Director, Vaccine Education Center, The Children's Hospital of Philadelphia; Professor of Pediatrics, Maurice R. Hilleman Professor of Vaccinology, Perelman School of Medicine, The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania; Kathryn M. Edwards, MD, Sarah H. Sell and Cornelius Vanderbilt Chair in Pediatrics, Professor of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee and Stanley A. Plotkin, MD, Emeritus Professor of Pediatrics, University of Pennsylvania, Emeritus Professor, Wistar Institute, Former Chief, Division of Infectious Diseases, The Children's Hospital of Philadelphia, Philadelphia, PA; Former Medical and Scientific Director, Pasteur Merieux Connaught (now Sanofi Pasteur), Marnes-la-Coquette, France |
| Table of Content | Section 1: General Aspects of Vaccination 1 A short history of vaccination 2 Vaccine immunology 3 Non-specific effects of Vaccines 4 Correlates of protection 5 The vaccine industry 6 Vaccine manufacturing 7 Evolution of adjuvants across the centuries 8 Vaccine Additives and Manufacturing Residuals in Vaccines Licensed in the United States 9 Passive immunization Section 2: Licenced Vaccines and Vaccines in Development 10 General immunization practices 11 Human Adenovirus vaccines 12 Anthrax vaccines 13 EMERGING Diseases and Emerging VACCINES (Military) 14 Cancer vaccines 15 Cholera vaccines 16 Combination vaccines 17 Coronavirus 18 Cytomegalovirus vaccines 19 Dengue vaccines 20 Diarrhea caused by bacteria 21 Diphtheria toxoid 22 Ebola vaccines 23 Enterovirus 24 Epstein-Barr virus vaccines 25 Haemophilus influenzae type b vaccines 26 Hepatitis A vaccines 27 Hepatitis B vaccines 28 Hepatitis C vaccines 29 Hepatitis E vaccines 30 Herpes simplex virus vaccines 31 Human immunodeficiency virus vaccines 32 Human papillomavirus vaccines 33 Inactivated influenza vaccines 34 Influenza vaccine-live 35 Japanese encephalitis vaccines 36 Lyme disease vaccines 37 Malaria vaccines 38 Measles vaccine 39 Meningococcal Capsular A, B, C, W, and Y Conjugate Vaccines 40 Meningococcal Capsular B Vaccines 41 Mumps vaccines 42 Noninfectious disease vaccines 43 Norovirus 44 Norovirus 44 Parasitic disease vaccines 45 Pertussis vaccines 46 Plague vaccines 47 Pneumococcal conjugate vaccine and pneumococcal common protein vaccines 48 Pneumococcal polysaccharide vaccines 49 Poliovirus vaccine-inactivated 50 Poliovirus vaccine-live 51 Rabies vaccines 52 Respiratory syncytial virus vaccines 53 Rotavirus vaccines 54 Rubella vaccine 55 Smallpox and vaccinia 56 Staphylococcus aureus vaccines 57 Streptococcus group A vaccines 58 Streptococcus group B vaccines 59 Tetanus toxoid 60 Tick-borne encephalitis virus vaccines 61 Tuberculosis vaccines 62 Typhoid fever vaccines 63 Varicella vaccine 64 Yellow fever vaccine 65 Zika vaccine 66 Zoster vaccine 67 Technologies for making new vaccines 68 Section 3: New Technologies 68 The development of gene-based vectors for immunization 69 Technologies to Improve Immunization 70 Vaccination of immunocompromised hosts 71 Section 4: Vaccination in Special Groups 71 Vaccines for international travel 72 Vaccines for health care personnel 73 Vaccination of pregnant women 74 Vaccination of pregnant women 74 Immunization in the United States 75 Immunization in Europe 76 Section 5: Public Health and Regulatory Issues 76 Immunization in the Asia-Pacific region 77 Immunization in developing countries 78 Community Protection 79 Economic analyses of vaccine policies 80 Regulation and testing of vaccines IN THE US 81 Regulation of vaccines in Europe 82 Regulation of vaccines in low and middle-income countries 83 Vaccine safety 84 Vaccine hesitancy 85 Legal issues 86 Ethics Appendix Foreword |
| Publication Date | 31-03-2023 |
| Pages | 1720 |
| trim | 276 x 216 (8 1/2 x 10 7/8) |
| Stock Status | In Stock |
| deltacomm1code | Books |
